Comparison
NMN vs Metformin
NMN
Nicotinamide mononucleotide — NAD+ precursor. Studied for cellular aging and metabolic health.
Metformin
Anti-diabetic medication studied for longevity. AMPK activator. Glucose normalization.
| Field | NMN | Metformin |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 500–2000mg |
| Half-life | — | — |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 600 | 23000 |
The comparison in plain English
Auto-generated from dataNMN and Metformin are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide — NAD+ precursor. Metformin Anti-diabetic medication studied for longevity.
Bottom line
NMN (evidence B, safety 5/5) has a stronger evidence base than Metformin (evidence A, safety 4/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.
Choose Metformin if
Metformin is the better fit when your goal aligns with its mechanism (Activates AMP-activated protein kinase (AMPK), the cellular energy sensor that mimics caloric restriction signalling) and the dose range (500–2000mg) suits your protocol. Half-life is —h.